REPORT ID 1197

United States Multiple Sclerosis (MS) Drugs Market Report 2017

Publish Date
05-Dec-17
Pages
105
Format
Electronic (PDF)

In this report, the United States Multiple Sclerosis (MS) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Multiple Sclerosis (MS) Drugs in these regions, from 2012 to 2022 (forecast).

United States Multiple Sclerosis (MS) Drugs market competition by top manufacturers/players, with Multiple Sclerosis (MS) Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Bayer AG
    Bayhill Therapeutics
    Biogen Idec
    Cinnagen
    Daiichi Sankyo
    Eli Lilly
    Fast Forward Llc
    Antisense Therapeutics
    Apitope
    Five Prime Therapeutics
    Genmab
    Artielle Immunotherapeutics
    Genzyme
    Glaxosmithkline
    Gw Pharmaceuticals
    Innate Immunotherapeutics

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Copaxone (Glatiramer Acetate, Copolymer 1)
    Novantrone (Mitoxantrone)
    Gilenya (Fingolimod, Fty720)
    Aubagio (Teriflunomide)
    Tecfidera (Dimethyl Fumarate)
    Firategrast (Sb683699, T-0047)
    Siponimod (Baf312)
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    RRMS
    SPMS
    PPMS
    PRMS

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Multiple Sclerosis (MS) Drugs Market Report 2017
1 Multiple Sclerosis (MS) Drugs Overview
    1.1 Product Overview and Scope of Multiple Sclerosis (MS) Drugs
    1.2 Classification of Multiple Sclerosis (MS) Drugs by Product Category
        1.2.1 United States Multiple Sclerosis (MS) Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
        1.2.2 United States Multiple Sclerosis (MS) Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
        1.2.3 Copaxone (Glatiramer Acetate, Copolymer 1)
        1.2.4 Novantrone (Mitoxantrone)
        1.2.5 Gilenya (Fingolimod, Fty720)
        1.2.6 Aubagio (Teriflunomide)
        1.2.7 Tecfidera (Dimethyl Fumarate)
        1.2.8 Firategrast (Sb683699, T-0047)
        1.2.9 Siponimod (Baf312)
        1.2.10 Others
    1.3 United States Multiple Sclerosis (MS) Drugs Market by Application/End Users
        1.3.1 United States Multiple Sclerosis (MS) Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
        1.3.2 RRMS
        1.3.3 SPMS
        1.3.4 PPMS
        1.3.5 PRMS
    1.4 United States Multiple Sclerosis (MS) Drugs Market by Region
        1.4.1 United States Multiple Sclerosis (MS) Drugs Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 The West Multiple Sclerosis (MS) Drugs Status and Prospect (2012-2022)
        1.4.3 Southwest Multiple Sclerosis (MS) Drugs Status and Prospect (2012-2022)
        1.4.4 The Middle Atlantic Multiple Sclerosis (MS) Drugs Status and Prospect (2012-2022)
        1.4.5 New England Multiple Sclerosis (MS) Drugs Status and Prospect (2012-2022)
        1.4.6 The South Multiple Sclerosis (MS) Drugs Status and Prospect (2012-2022)
        1.4.7 The Midwest Multiple Sclerosis (MS) Drugs Status and Prospect (2012-2022)
    1.5 United States Market Size (Value and Volume) of Multiple Sclerosis (MS) Drugs (2012-2022)
        1.5.1 United States Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2012-2022)
        1.5.2 United States Multiple Sclerosis (MS) Drugs Revenue and Growth Rate (2012-2022)

2 United States Multiple Sclerosis (MS) Drugs Market Competition by Players/Suppliers
    2.1 United States Multiple Sclerosis (MS) Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
    2.2 United States Multiple Sclerosis (MS) Drugs Revenue and Share by Players/Suppliers (2012-2017)
    2.3 United States Multiple Sclerosis (MS) Drugs Average Price by Players/Suppliers (2012-2017)
    2.4 United States Multiple Sclerosis (MS) Drugs Market Competitive Situation and Trends
        2.4.1 United States Multiple Sclerosis (MS) Drugs Market Concentration Rate
        2.4.2 United States Multiple Sclerosis (MS) Drugs Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Multiple Sclerosis (MS) Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Multiple Sclerosis (MS) Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)
    3.1 United States Multiple Sclerosis (MS) Drugs Sales and Market Share by Region (2012-2017)
    3.2 United States Multiple Sclerosis (MS) Drugs Revenue and Market Share by Region (2012-2017)
    3.3 United States Multiple Sclerosis (MS) Drugs Price by Region (2012-2017)

4 United States Multiple Sclerosis (MS) Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
    4.1 United States Multiple Sclerosis (MS) Drugs Sales and Market Share by Type (Product Category) (2012-2017)
    4.2 United States Multiple Sclerosis (MS) Drugs Revenue and Market Share by Type (2012-2017)
    4.3 United States Multiple Sclerosis (MS) Drugs Price by Type (2012-2017)
    4.4 United States Multiple Sclerosis (MS) Drugs Sales Growth Rate by Type (2012-2017)

5 United States Multiple Sclerosis (MS) Drugs Sales (Volume) by Application (2012-2017)
    5.1 United States Multiple Sclerosis (MS) Drugs Sales and Market Share by Application (2012-2017)
    5.2 United States Multiple Sclerosis (MS) Drugs Sales Growth Rate by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6  United States Multiple Sclerosis (MS) Drugs Players/Suppliers Profiles and Sales Data
    6.1 Bayer AG
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Bayhill Therapeutics
        6.2.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Biogen Idec
        6.3.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Cinnagen
        6.4.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Daiichi Sankyo
        6.5.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Eli Lilly
        6.6.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Fast Forward Llc
        6.7.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Antisense Therapeutics
        6.8.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Apitope
        6.9.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Five Prime Therapeutics
        6.10.2 Multiple Sclerosis (MS) Drugs Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Genmab
    6.12 Artielle Immunotherapeutics
    6.13 Genzyme
    6.14 Glaxosmithkline
    6.15 Gw Pharmaceuticals
    6.16 Innate Immunotherapeutics

7 Multiple Sclerosis (MS) Drugs Manufacturing Cost Analysis
    7.1 Multiple Sclerosis (MS) Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Multiple Sclerosis (MS) Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Multiple Sclerosis (MS) Drugs Market Size (Value and Volume) Forecast (2017-2022)
    11.1 United States Multiple Sclerosis (MS) Drugs Sales Volume, Revenue Forecast (2017-2022)
    11.2 United States Multiple Sclerosis (MS) Drugs Sales Volume Forecast by Type (2017-2022)
    11.3 United States Multiple Sclerosis (MS) Drugs Sales Volume Forecast by Application (2017-2022)
    11.4 United States Multiple Sclerosis (MS) Drugs Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer